載入...
HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation
Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...
Na minha lista:
| 發表在: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/ https://ncbi.nlm.nih.gov/pubmed/32956454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|